Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy

XIA Yong; HUANG Jian; QIAN Qijun

doi:10.3969/j.issn.1006-0111.2016.04.023

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 34 Issue 4

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2016 > 34(4): 372-376

XIA Yong, HUANG Jian, QIAN Qijun. Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 372-376. doi: 10.3969/j.issn.1006-0111.2016.04.023

Citation:

XIA Yong, HUANG Jian, QIAN Qijun. Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 372-376. doi: 10.3969/j.issn.1006-0111.2016.04.023

Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy

doi: 10.3969/j.issn.1006-0111.2016.04.023

1.
Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital affliated to Second Military Medical University, Shanghai 200438, China
2.
the Third Department of Hepatic surgery, Eastern Hepatobiliary Surgical Hospital affliated to Second Military Medical University, Shanghai 200438, China

Received Date: 2016-01-06
Rev Recd Date: 2016-05-16

Abstract

The great potential of cell therapy based on chimeric antigen receptor (CAR) has been demonstrated in the treatment of malignant tumors through 25 years of research.A large number of experimental and clinical data have been reported in recent years.This review compares and analyzes these data to discuss how to enhance the efficacy of CAR-T cell therapy in the treatment of unresectable malignant tumors and to summarize the safety issues and solution strategies of CAR-T cell technology in the treatment of malignant tumors.
- chimeric antigen receptor (CAR),
- adoptive cell immunotherapy,
- tumors

References

[1]	Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells:CARs take the front seat forhematologic malignancies[J]. Blood, 2014, 123(17):2625-2635.
[2]	陈杰, 王宇环, 罗成林, 等. 嵌合抗原受体T细胞介绍及抗肿瘤临床应用[J]. 中国细胞生物学学报, 2014, 36(2):228-235.
[3]	张少华,毕经旺. 嵌合抗原受体修饰T细胞在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志,2014,41(7):495-499.
[4]	Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med,2014,371(16):1507-1517.
[5]	徐云云, 金润铭. 血液肿瘤治疗中嵌合抗原受体基因修饰T淋巴细胞作用[J]. 中国实用儿科杂志,2013,28(8):626-629.
[6]	Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118(23):6050-6056.
[7]	Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells:clinical evaluation and management of on-target toxicity[J]. Mol Ther,2013,21(4):904-912.
[8]	Rizvi NA, Mazières J, Planchard D, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J]. Lancet Oncol,2015, 16(3):257-265.
[9]	Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014,515(7528):568-571.
[10]	Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression[J]. Clin Dev Immunol,2012,2012:656340.
[11]	John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells[J]. Clin Cancer Res,2013,19(20):5636-5646.
[12]	John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy[J]. Oncoimmunology,2013,2(10):e26286.
[13]	Yan Y, Li S, Jia T, et al. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity[J].Tumour Biol,2015,36(6):4535-4543.
[14]	Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors[J].Cancer Res,2014,74(18):5195-5205.
[15]	鹿萍,郝莎, 袁卫平,等.嵌合抗原受体——癌症免疫治疗的新希望[J]. 中华医学杂志,2015,95(4):311-314.
[16]	Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J]. Nat Med,2015,21(6):581-590.
[17]	Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137(4-1BB)[J]. Cancer Res,2011,71(13):4617-4627.
[18]	Zhao Z, Condomines M, van der Stegen SJ, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J]. Cancer Cell,2015,28(4):415-428.
[19]	Prapa M, Caldrer S, Spano C, et al. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing[J]. Oncotarget,2015,6(28):24884-24894.
[20]	Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J]. J Clin Oncol,2015,33(15):1688-1696.
[21]	Maus MV, June CH. CARTs on the road for myeloma[J]. Clin Cancer Res,2014,20(15):3899-3901.
[22]	Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design[J]. Cancer Discov,2013,3(4):388-398.
[23]	Kalaitsidou M, Kueberuwa G, Schutt A, et al. CAR T-cell therapy:toxicity and the relevance of preclinical models[J]. Immunotherapy,2015,7(5):487-497.
[24]	蔡慧, 赵莲君, 邹征云. 嵌合抗原受体基因修饰T淋巴细胞在肿瘤免疫治疗中的研究[J]. 现代肿瘤医学,2014, 22(11):2730-2734.
[25]	Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice[J]. Cancer Res,2015,75(17):3596-3607.
[26]	Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells[J]. Nat Biotechnol,2013,31(1):71-75.
[27]	Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling[J]. J Clin Immunol,2012,32(5):1059-1070.
[28]	Caruso HG, Hurton LV, Najjar A, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity[J]. Cancer Res,2015,75(17):3505-3518.
[29]	Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Sci Transl Med,2014,6(224):224-225.
[30]	Wu CY, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor[J].Science,2015,350(6258):aab4077.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3988) PDF downloads(1173) Cited by()

Proportional views

Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy

1. Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital affliated to Second Military Medical University, Shanghai 200438, China

2. the Third Department of Hepatic surgery, Eastern Hepatobiliary Surgical Hospital affliated to Second Military Medical University, Shanghai 200438, China

Received Date: 2016-01-06

Rev Recd Date: 2016-05-16

Key words:

Abstract: The great potential of cell therapy based on chimeric antigen receptor (CAR) has been demonstrated in the treatment of malignant tumors through 25 years of research.A large number of experimental and clinical data have been reported in recent years.This review compares and analyzes these data to discuss how to enhance the efficacy of CAR-T cell therapy in the treatment of unresectable malignant tumors and to summarize the safety issues and solution strategies of CAR-T cell technology in the treatment of malignant tumors.

HTML

Reference (30)

[1]	Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells:CARs take the front seat forhematologic malignancies[J]. Blood, 2014, 123(17):2625-2635.
[2]	陈杰, 王宇环, 罗成林, 等. 嵌合抗原受体T细胞介绍及抗肿瘤临床应用[J]. 中国细胞生物学学报, 2014, 36(2):228-235.
[3]	张少华,毕经旺. 嵌合抗原受体修饰T细胞在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志,2014,41(7):495-499.
[4]	Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med,2014,371(16):1507-1517.
[5]	徐云云, 金润铭. 血液肿瘤治疗中嵌合抗原受体基因修饰T淋巴细胞作用[J]. 中国实用儿科杂志,2013,28(8):626-629.
[6]	Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118(23):6050-6056.
[7]	Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells:clinical evaluation and management of on-target toxicity[J]. Mol Ther,2013,21(4):904-912.
[8]	Rizvi NA, Mazières J, Planchard D, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J]. Lancet Oncol,2015, 16(3):257-265.
[9]	Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014,515(7528):568-571.
[10]	Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression[J]. Clin Dev Immunol,2012,2012:656340.
[11]	John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells[J]. Clin Cancer Res,2013,19(20):5636-5646.
[12]	John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy[J]. Oncoimmunology,2013,2(10):e26286.
[13]	Yan Y, Li S, Jia T, et al. Combined therapy with CTL cells and oncolytic adenovirus expressing IL-15-induced enhanced antitumor activity[J].Tumour Biol,2015,36(6):4535-4543.
[14]	Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors[J].Cancer Res,2014,74(18):5195-5205.
[15]	鹿萍,郝莎, 袁卫平,等.嵌合抗原受体——癌症免疫治疗的新希望[J]. 中华医学杂志,2015,95(4):311-314.
[16]	Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J]. Nat Med,2015,21(6):581-590.
[17]	Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137(4-1BB)[J]. Cancer Res,2011,71(13):4617-4627.
[18]	Zhao Z, Condomines M, van der Stegen SJ, et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J]. Cancer Cell,2015,28(4):415-428.
[19]	Prapa M, Caldrer S, Spano C, et al. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing[J]. Oncotarget,2015,6(28):24884-24894.
[20]	Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J]. J Clin Oncol,2015,33(15):1688-1696.
[21]	Maus MV, June CH. CARTs on the road for myeloma[J]. Clin Cancer Res,2014,20(15):3899-3901.
[22]	Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design[J]. Cancer Discov,2013,3(4):388-398.
[23]	Kalaitsidou M, Kueberuwa G, Schutt A, et al. CAR T-cell therapy:toxicity and the relevance of preclinical models[J]. Immunotherapy,2015,7(5):487-497.
[24]	蔡慧, 赵莲君, 邹征云. 嵌合抗原受体基因修饰T淋巴细胞在肿瘤免疫治疗中的研究[J]. 现代肿瘤医学,2014, 22(11):2730-2734.
[25]	Liu X, Jiang S, Fang C, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice[J]. Cancer Res,2015,75(17):3596-3607.
[26]	Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells[J]. Nat Biotechnol,2013,31(1):71-75.
[27]	Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling[J]. J Clin Immunol,2012,32(5):1059-1070.
[28]	Caruso HG, Hurton LV, Najjar A, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity[J]. Cancer Res,2015,75(17):3505-3518.
[29]	Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J]. Sci Transl Med,2014,6(224):224-225.
[30]	Wu CY, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor[J].Science,2015,350(6258):aab4077.

Message Board

Research progress on improving the anti-cancer activity and safety of the CAR-T cells therapy

doi: 10.3969/j.issn.1006-0111.2016.04.023

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views